ESSA Pharma Inc.

10:36 AM EST - ESSA Pharma Inc. : Reported financial results for the fiscal third quarter ended June 30, 2018. All references to "$" in this release refer to United States dollars, unless otherwise indicated. Cash on hand at June 30, 2018, was $18.1 million, with working capital of $14.8 million, reflecting the aggregate gross proceeds of the completed January 2018 financing, which totaled $26 million. ESSA recorded a net loss of $2.9 million ($0.50 loss per common share based on 5,776,098 weighted average common shares outstanding) for the quarter ended June 30, 2018, compared to net income of $3.6 million ($2.47 earnings per common share based on 1,454,960 weighted average common shares outstanding) for the quarter ended June 30, 2017. ESSA Pharma Inc. shares V.EPI are trading unchanged at $4.25.